Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

All-Spectrum Transradial Approach: Safer than Femoral

Original Title: Radial vs femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials.

Reference: Ferrante G et al. J Am Coll Cardiol Intv. 2016; Epub ahead of print.

 

acceso_radial_finalRegardless the type of coronary syndrome, the transradial approach results in lower mortality and complications compared to the femoral.

Some studies (especially on chronic and stable patients) have seen contradicting results as regards the advantages of the transradial approach over the femoral, which is why this meta-analyzis of 24 studies was carried out, involving over 22,843 patients with PCI in the context of ACS

  • without ST elevation
  • with ST elevation
  • in stable patients

The transradial approach showed lower risk of all cause death (OR 0.71, CI 95% 0.58 to 0.87) and lower risk of combined cardiovascular events (OR 0.84; CI 95% 0.75 to 0.94) in the general population.

The transradial approach was also associated to lower major bleeding rate (OR 0.53; CI 95% 0.42 to 0.65) and lower major vascular complications rate (OR 0.23; CI 95% 0.16 to 0.34).

Other important data resulting from this work is that MI and stroke rates resulted similar for both vascular access sites.

When analyzing outcomes according to clinical presentation, stable patients are those who benefit most from reduced major bleeding. In the group of ACS patients, ST elevation MI patients saw the greatest benefit with transradial approach.

Lastly, the experienced centers obtained the highest benefits vs. femoral approach.

 

Conclusion

The transradial approach reduces mortality and combined events, and improves safety because of reduced bleeding and vascular complications, compared to the femoral access.

 

Editorial Comment

The benefit of the transradial approach seems out of question; however, a great randomized study would be useful to understand the mechanisms behind this advantage. Reduced major bleeding seems to be the main reason behind mortality decrease, though it may not be enough: there may be other, hidden mechanisms involved.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or any ideas here below.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...